Format: 1-hour Virtual Thought Leadership Session
Date & Time: Monday, 23rd September, 1:30–2:30 PM BST / 8:30–9:30 AM EST
Platform: Zoom
1:30 PM – Thought Leader Interview (20 mins)
Title: Engineering the Future of ADCs: Innovation, Efficacy, and Clinical Integration
Interview with: Dr. Victor Jeffrey Leyton, Associate Professor, School of Pharmaceutical Sciences and Department of Cellular and Molecular Medicine, University of Ottawa
2:00 PM – Panel Discussion (30 mins)
Title: Overcoming Design and Clinical Challenges in Antibody–Drug Conjugates (ADCs)
Discussion Topics:
- How tumour heterogeneity, the tumour microenvironment (TME), and cell-surface biology should inform ADC design
- Current limitations in how biologic and chemical domains collaborate – how do we bridge that gap?
- Lessons learned from clinically successful (and unsuccessful) ADCs: what the biology told us in hindsight
- Role of real-world clinical data in rethinking preclinical models and linker–payload matching
- Vision: where does the field go in 3–5 years in tumour-selective chemical engineering?
Moderator:
Victor Jeffrey Leyton, Associate Professor, School of Pharmaceutical Sciences and Department of Cellular and Molecular Medicine, University of Ottawa
Panellists:
Sophia N. Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London
Sharsti Sandall, Executive Director, Pfizer
To attend this Thought Leadership session you need to be a Premium LifeScienceXchange member.
Secure all the benefits and sign-up for Premium membership now
*If you’re already a Premium member your exclusive invite will be sent direct to your inbox